|
| Register for our Free Newsletters |
|
 |
|
|
|
|
|
|
|
|
| Other Carouselweb publications |
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
Rosetta licenses MGB Probe technology to support new PCR Diagnostic Assays
|
|
Rosetta Genomics
: 12 December, 2007 (New Product) |
|
Rosetta Genomics has selected Nanogen’s MGB Probe technology as the platform for its new range of microRNA-based diagnostic products, the first of which are expected to launch in 2008.
|
|
Rosetta has licensed the MGB Probe technology from Nanogen. The licensing deal will allow Rosetta Genomics to combine the technical performance advantages of Nanogen's MGB Probe technology with the company's own proprietary microRNA biomarkers to create a line of quantitative real-time PCR diagnostic tests.
Leveraging microRNAs' strong tissue specificity and involvement in the regulation of a large number of human genes, Rosetta Genomics has identified specific microRNA signatures that it believes will allow for accurate diagnosis of various cancers.
Rosetta Genomics expects the following three tests to launch in 2008:
- Differentiating squamous from non squamous lung cancer - As current targeted therapy for lung cancer can cause haemorrhaging in squamous cell lung cancer patients, differentiating between the cancer types is critical. Rosetta Genomics has identified several microRNA biomarkers that may allow for sensitive and specific identification of squamous cell carcinoma.
- Differentiating mesothelioma from lung adenocarcinoma - Rosetta Genomics has identified a panel of microRNA biomarkers potentially allowing for differentiation between these cancer types.
Cancer of Unknown Primary (CUP) - This test is designed to assist clinicians to accurately identify the origin of metastases. In three to five percent of all cancer patients, clinicians cannot identify the origin of a patients' tumour. The information is crucial for determining treatment type. Rosetta Genomics has developed a panel of microRNA biomarkers potentially able to identify approximately thirty cancers
'Our proprietary microRNA detection and quantitation technologies are at the heart of our sensitive diagnostic products,' noted Amir Avniel, president and CEO of Rosetta Genomics.' Using very small amounts of tissue samples or body fluids, we are able to detect microRNAs on the order of single molecules, as well as differentiate microRNAs with only a single nucleotide mismatch. We look forward to the launch of our first diagnostic products in 2008.'
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
